Zosano Pharma Corp (NASDAQ:ZSAN)’s share price dropped 0% during mid-day trading on Friday . The company traded as low as $0.52 and last traded at $0.53. Approximately 583,931 shares traded hands during mid-day trading, an increase of 46% from the average daily volume of 401,026 shares. The stock had previously closed at $0.53.
Separately, ValuEngine upgraded Zosano Pharma from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st.
The firm has a market capitalization of $20.72 and a price-to-earnings ratio of -0.44.
In other news, Director Kenneth Greathouse acquired 95,000 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was purchased at an average cost of $0.62 per share, for a total transaction of $58,900.00. Following the acquisition, the director now owns 95,000 shares of the company’s stock, valued at $58,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders bought a total of 200,000 shares of company stock valued at $123,450 over the last quarter. Company insiders own 2.83% of the company’s stock.
An institutional investor recently raised its position in Zosano Pharma stock. Northern Trust Corp raised its holdings in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 591.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,234 shares of the biotechnology company’s stock after purchasing an additional 67,774 shares during the period. Northern Trust Corp owned 0.20% of Zosano Pharma worth $112,000 at the end of the most recent reporting period. Institutional investors own 19.41% of the company’s stock.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.